RecruitingNCT05793502

Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK

Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Enrollment

1,000 participants

Start Date

Jul 4, 2023

Study Type

OBSERVATIONAL

Conditions

Consented to Participate in the Trial and Signed an ICF Patients With an Indication for PM Implantation or CRTP

Summary

This study is aimed to assess the effectiveness and safety of LBBaP with Solia S and Selectra 3D in the Chinese population by analyzing the operation success rate and the system stability during follow-up visits.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Solia S and Selectra 3D Developed by BIOTRONIK for people with consented to participate in the trial and signed an icf and patients with an indication for pm implantation or crtp. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESolia S and Selectra 3D Developed by BIOTRONIK

LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK

Locations(1)

Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05793502

Related Trials

High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)

NCT074455031 location